$155 Million is the total value of Essex Woodlands Management, Inc.'s 8 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RVNC | REVANCE THERAPEUTICS INC | $49,462,000 | -8.8% | 3,342,047 | 0.0% | 31.84% | +25.9% | |
| EYPT | EYEPOINT PHARMACEUTICALS INC | $42,747,000 | -34.2% | 41,909,219 | 0.0% | 27.52% | -9.2% | |
| AXGN | AXOGEN INC | $25,272,000 | -41.9% | 2,429,999 | 0.0% | 16.27% | -19.8% | |
| VERO | VENUS CONCEPT, INC. | $24,913,000 | -24.5% | 7,017,856 | 0.0% | 16.04% | +4.3% | |
| CBIO | CATALYST BIOSCIENCES INC | $344,000 | -35.7% | 78,622 | 0.0% | 0.22% | -11.6% | |
| ELGXQ | ENDOLOGIX INC | $89,000 | -87.6% | 125,747 | 0.0% | 0.06% | -82.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MEDICINOVA INC | 42 | Q3 2023 | 6.5% |
| REVANCE THERAPEUTICS INC | 39 | Q3 2023 | 44.6% |
| AXOGEN INC | 26 | Q4 2021 | 43.3% |
| ENDOLOGIX INC | 24 | Q1 2019 | 22.5% |
| ABIOMED INC | 20 | Q1 2018 | 52.1% |
| CORIUM INTL INC | 20 | Q1 2019 | 23.5% |
| TELA BIO, INC. | 16 | Q3 2023 | 31.5% |
| VENUS CONCEPT, INC. | 16 | Q3 2023 | 21.3% |
| ACURA PHARMACEUTICALS INC | 15 | Q1 2019 | 1.4% |
| CATALYST BIOSCIENCES INC | 15 | Q1 2019 | 1.0% |
View Essex Woodlands Management, Inc.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Essex Woodlands Management, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.